PFE Pfizer Inc.

Mentions (100)

• Newszacks.com·20h ago·Negative

  Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation J&J's diversified portfolio, new drug launches and sales growth give it an edge despite Pfizer's cheaper valuation and higher yield.

  View source ↗
• News (RSS)fool·1d ago·Neutral

  Better High-Yield Dividend Stock: Pfizer or Novo Nordisk? Novo Nordisk covers its dividend, and Pfizer doesn't, but investors appear increasingly worried about Novo's future.

  View source ↗
• Newsfool.com·1d ago·Neutral

  Better High-Yield Dividend Stock: Pfizer or Novo Nordisk? Novo Nordisk is a leading GLP-1 company, but its portfolio beyond that is limited.  Pfizer hasn't entered the GLP-1 race yet, but the company has a diversified business and a long history of success.

  View source ↗
• Newsfool.com·1d ago·Negative

  Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield Pfizer shares have underperformed since 2021, with the recent poor performance reflecting concerns about impending patent expirations. The pharmaceutical company, however, has been repositioning itself for this unavoidable headwind, setting up firmer growth beginning in 2029.

  View source ↗
• Newsfool.com·2d ago·Positive

  3 Dirt Cheap Dividend Stocks Worth Buying in October There are blazing deals for some of the top healthcare stocks -- companies with proven track records and dividend yields as high as 6%.

  View source ↗
• News (RSS)seekingalpha·2d ago·Neutral

  AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot

  View source ↗
• News (Marketaux)gurufocus.com·3d ago·Positive

  Pfizer (PFE) Reports Positive Phase 3 Trial Results for LITFULO in Vitiligo Treatment On October 02, 2026, Pfizer <em[+274 characters]

  View source ↗
• News (RSS)fool·3d ago·Positive

  Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? Novo Nordisk boasts a 33% net margin and fortress balance sheet, while Pfizer trades cheaper but faces major patent cliffs through 2030.

  View source ↗
• Newsfool.com·3d ago·Positive

  Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? Novo Nordisk maintains high profitability through its specialization in chronic disease management and metabolic health. Pfizer is aggressively diversifying its portfolio through strategic acquisitions in oncology and obesity to counter upcoming patent expirations.

  View source ↗
• Newsbusinesswire.com·3d ago·Negative

  Pfizer's LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO® (ritlecitinib) as a once-daily oral treatment across a wide range of disease extent. In the two studies, TRANQUILLO 2 and TRANQUILLO, LITFULO 100 mg and 50 mg, respectively, significantly improved facial and total body repigmentation comp…

  View source ↗
• Newsfool.com·4d ago·Neutral

  Pfizer Is Down 34% Over the Last 5 Years. Here's Why Its 6% Dividend Yield Might Finally Be Worth the Risk. Pfizer has faced the challenges of declining coronavirus portfolio revenue and patent expirations in recent years. Today, the company's investments in new products and acquisitions are starting to pay off.

  View source ↗
• Newszacks.com·4d ago·Positive

  Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know Pfizer (PFE) closed the most recent trading day at $28.1, moving 1.47% from the previous trading session.

  View source ↗
• News (RSS)zerohedge·4d ago·Neutral

  … tirzepatide. Novo filed CagriSema with the FDA in December 2025 and expects a decision by late 2026. Novo also lost the fight for the next amylin drug. In November, Pfizer outbid it for Metsera in a roughly $10 billion bidding war over the biotech's monthly amylin candidate. Meanwhile Mounjaro overtook Merck's Keytruda as the world's best-selling drug in the first quarter, with $8.7 billion in sales. Lilly plans to begin late-stage studies of the new combination by year-end, using a single co-f…

  View source ↗
• Newsbusinesswire.com·5d ago·Negative

  Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermatitis (AD). The study met its primary endpoint, demonstrating a statistically significant increase in the percentage of participants achieving EASI-75* (≥75% reduction in the Eczema Area and Severity Index) at Wee…

  View source ↗
• News (RSS)economictimes·6d ago·Neutral

  Medico Remedies among 5 Healthcare stocks hitting 52-week low; slipped up to 48% in a month The Sensex fell 242 points to 72,529 as five BSE Healthcare Index stocks touched fresh 52-week lows. Medico Remedies, Pfizer, AstraZeneca Pharma India, Sanofi Consumer Healthcare India and Eris Lifesciences recorded their lowest prices in a year.

  View source ↗
• Newszacks.com·6d ago·Negative

  Novo vs. Pfizer: Which Large Drugmaker Offers Better Growth Prospects? NVO and PFE offer different growth paths, with diversified portfolios, pipelines and near-term challenges shaping their outlooks.

  View source ↗
• Newsglobenewswire.com·7d ago·Neutral

  Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer BRISBANE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the achievement of a $7 million research milestone under its strategic collaboration with Pfizer for the discovery and development of deg…

  View source ↗
• Newsseekingalpha.com·7d ago·Neutral

  … Support A Buy Through The LOE Trough Pfizer is rated a Buy, with a compelling risk-reward profile despite near-term COVID normalization and patent expiry headwinds. PFE's new and acquired products are delivering strong double-digit growth, helping offset losses from COVID and the upcoming loss of exclusivity events. Cost-restructuring initiatives targeting $9.7 billion in savings by 2029 should cushion earnings and support margin resilience through the LOE-heavy period.

  View source ↗
• Newszacks.com·7d ago·Neutral

  Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

  View source ↗
• Newsbusinesswire.com·8d ago·Negative

  Pfizer Advances Today's Cancer Care and Tomorrow's Potential Breakthroughs at ESMO NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026 in Madrid, Spain. The presentations include 11 oral presentations spanning Pfizer's established medicines and late-stage pipeline across its disease areas of focus, …

  View source ↗
• News (RSS)seekingalpha·10d ago·Positive

  Pfizer: Buy Before The Street Catches Up To Its Own Numbers

  View source ↗
• Newsseekingalpha.com·10d ago·Positive

  …isconnect between management's bullish long-term growth guidance and a flat consensus earnings curve. Consensus models a permanent post-2026 revenue/EPS decline, but PFE's $13B product base is compounding at 20%+, and the Vyndamax settlement secures $2–3B annual revenue through 2031. Management guides to high single-digit revenue CAGR from 2028 to 2033, implying 2033 revenue of $21–26B above even the Street's highest estimate.

  View source ↗
• News (RSS)fool·10d ago·Negative

  AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.

  View source ↗
• PodcastCompound And Friends·10d ago·Negative

  … the GFC. I mean, this is a study, this is like a pole with business, typically. Yeah. That's what we're about to do. And it was in the sort of in the same position. Pfizer had all these boring back office financial businesses. And there was tons of reliability. And then I guess the CEO ran it off the cliff or something. But like, it went from being this boring thing to a stock that fell 20%. And one day. I think the CEO ended up working for the Trump administration. He sold his stock at basical…

  View source ↗
• Newsseekingalpha.com·11d ago·Negative

  …ing Plans Pfizer Inc. faces a significant loss of exclusivity wall, but the biopharma has a new drug pipeline and cost-cutting plans to cover most of the sales hits. PFE guided 2026 revenues to $61.5B, with COVID-19 revenues now minimal and high single-digit growth projected starting in 2029. The company has another major cost reduction plan for savings of up to $4B to offset most gross profit losses from LoEs, supporting stable EPS near $2.90 through 2028.

  View source ↗
• Newszacks.com·11d ago·Negative

  Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick? AbbVie and Pfizer are reshaping their growth strategies as new drugs, acquisitions, pipelines and patent challenges shape their outlooks.

  View source ↗
• News247wallst.com·12d ago·Neutral

  Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most investors get wrong.

  View source ↗
• News247wallst.com·13d ago·Positive

  3 Dividend Stocks Trading Cheap Enough to Buy Meaningful Stakes for Under $1,000 AT&T, Verizon, and Pfizer all trade under $50 a share, but a low entry price and genuine value are two very different things, and only one of these three high-yield names carries a coverage story that should make income investors

  View source ↗
• Newsfool.com·13d ago·Neutral

  Pfizer, Kraft, and UPS All Yield More Than 6%. Which of These Dividend Stocks Is the Safest Option Today? Pfizer, UPS, and Kraft are all high-yielding stocks that come with varying levels of risk. They're all generating positive free cash flow, but their payout ratios don't look good.

  View source ↗
• News (RSS)seekingalpha·13d ago·Positive

  Pfizer: A Quietly Outperforming High-Dividend Idea, Pipeline On Watch (Upgrade)

  View source ↗
• Newsseekingalpha.com·13d ago·Positive

  Pfizer: A Quietly Outperforming High-Dividend Idea, Pipeline On Watch (Upgrade) Pfizer is upgraded to buy, supported by a low valuation, strong free cash flow, and a high 6.2% dividend yield. PFE delivered a Q2 double beat, raised full-year revenue guidance, and benefits from pipeline progress, though COVID-19 product sales guidance was trimmed. Technical momentum is building, with a golden cross and bullish rounded bottom pattern, but resistance remains near $30.

  View source ↗
• News (Marketaux)finance.yahoo.com·13d ago·Positive

  Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth? Two intriguing dividend stocks that can [+327 characters]

  View source ↗
• Newsseekingalpha.com·13d ago·Positive

  Pfizer Inc. (PFE) Presents at U.S. All Stars Conference Transcript Pfizer Inc. (PFE) Presents at U.S. All Stars Conference Transcript

  View source ↗
• Newsseekingalpha.com·13d ago·Neutral

  Pfizer: A Conservative Valuation Leaves Room For A Post-LOE Re-Rating Pfizer remains a Buy, with valuation reflecting LOE risks and attractive risk-reward as the company executes on post-LOE growth strategies. PFE delivered a strong quarter, raising revenue guidance to $61.5B, driven by non-COVID portfolio strength and past acquisitions. Operational efficiency programs target $9.7B in cost savings through 2029, supporting ongoing R&D investment, deleveraging, and a robust 6.22% dividend yield.

  View source ↗
• Newsseekingalpha.com·13d ago·Negative

  Pfizer: The Market Won't Pay For 2029 Until It Can - Downgrading To Hold Pfizer is downgraded to Hold after a ~20% total return since October, as the rerating leg is complete and near-term catalysts are lacking. Current valuations (~8.7x EV/EBITDA) offer less cushion, with forward earnings visibility opaque and pipeline contributions still unproven. 2026 revenue guidance ($61.5B) and new product ramps are positive, but Vyndaqel softness and MFN Medicaid pricing rollout cloud the near-term outloo…

  View source ↗
• Newsmarketbeat.com·14d ago·Negative

  Pfizer Refocuses Growth Strategy as New Products Offset COVID Decline Pfizer NYSE: PFE has rebuilt its commercial model around newer and acquired products while reducing exposure to its COVID-19 franchise, according to Alexandre de Germay, the company's chief international commercial officer and executive vice president.

  View source ↗
• News (RSS)seekingalpha·14d ago·Positive

  Pfizer: The 10-Year Is At 5%, And I'm Still Buying This 6%+ Yield

  View source ↗
• Newsseekingalpha.com·14d ago·Positive

  Pfizer: The 10-Year Is At 5%, And I'm Still Buying This 6%+ Yield Pfizer remains a compelling income play, offering a 6.22% yield and trading at 9.3x 2026 consensus EPS amid a rising-rate environment. PFE's non-COVID portfolio is growing 5% operationally, with robust pipeline activity and $1.5B ahead of the original 2026 base business guidance. Management targets $9.7B in cost savings by 2029, supporting dividend coverage through the patent cliff and enabling R&D investment.

  View source ↗
• News (Marketaux)gurufocus.com·15d ago·Positive

  PFE Looks 4.5% Overvalued on GF Value™ as Dividend Sustainability Remains Key On September 21, 2026, Pfizer <[+226 characters]

  View source ↗
• Newsfool.com·15d ago·Neutral

  Pfizer Says Its Biggest Headwinds Are Finally Easing. Does That Change the Story for This Ultra-High-Yield Dividend Stock? Pfizer has made significant progress in addressing some of its challenges. However, the company still has a rocky road ahead.

  View source ↗
• News (Marketaux)business-standard.com·16d ago·Positive

  Pfizer to share higher overseas drug revenue with US health agency By Rachel Cohrs Zhang The US Department[+190 characters]

  View source ↗
• 4chan /biz/biz·16d ago·Negative

  >>62707846 Here's my non-4chany take on the COVID vax situation. 1.) The vax did f****** nothing. The point wasn't to prevent COVID or to poison people. Pfizer lobbied politicians to make the vax mandatory, and paid for by tax dollars. Which gave Pfizer more money which let them lobby more. That's why we saw thousands of unused shots going expired. The point wasn't to vaccinate people the point was to just sell them doses. 2.) Boomers were the only ones who were actually in danger of dying fr…

  View source ↗
• News (RSS)investing·16d ago·Negative

  Pfizer to share overseas drug revenue with HHS under pricing deal

  View source ↗
• News (RSS)fool·16d ago·Positive

  Is Pfizer an Excellent Dividend Stock to Buy? Pfizer has a history of developing treatments that generate billions in sales.

  View source ↗
• Newsfool.com·16d ago·Positive

  Is Pfizer an Excellent Dividend Stock to Buy? Pfizer (PFE +0.07%) has experienced unprecedented circumstances in the previous decade.

  View source ↗
• News (RSS)fool·17d ago·Neutral

  2 High-Yield Dividend Stocks to Buy and 1 to Avoid I'd buy Energy Transfer and Verizon stocks, and avoid Pfizer.

  View source ↗
• News247wallst.com·17d ago·Neutral

  Pfizer's Dividend Yield Is Enormous. But Is the Payout Still Growing? Pfizer has raised its dividend every year for over a decade, then something changed. Before you count on that 6% yield, find out what the payout's own behavior is quietly signaling about the company's financial confidence.

  View source ↗
• Newsfool.com·19d ago·Neutral

  Pfizer's Dividend Faces Big Questions. Here Are 3 Reasons It Should Survive. Pfizer's management remains firmly committed to maintaining the dividend. The company's growth portfolio is performing well.

  View source ↗
• News (RSS)yahoo·20d ago·Neutral

  Pfizer (PFE), Valneva (VALN) Lyme Vaccine Moves to EMA Review Despite Phase 3 Caveat

  View source ↗
• News (Marketaux)seekingalpha.com·21d ago·Positive

  Pfizer Inc. (PFE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Presentation Well, I'm very pleased to [+317 characters]

  View source ↗
• Newsmarketbeat.com·21d ago·Negative

  Pfizer Says Major Headwinds Are Easing as Pipeline, Obesity Plans Take Center Stage Pfizer NYSE: PFE Chairman and Chief Executive Officer Albert Bourla said the drugmaker has addressed several major headwinds that weighed on investor attention, including policy uncertainty, declining COVID-19-related demand and upcoming losses of exclusivity for certain products.

  View source ↗
• Newszacks.com·21d ago·Positive

  Can Pfizer Overcome Its COVID and Patent Cliff Headwinds? PFE faces COVID revenue declines and a patent cliff, but new products, acquisitions and a strong pipeline could fuel growth from 2029.

  View source ↗
• News247wallst.com·22d ago·Neutral

  Pfizer's 6% Yield Masks a Fragile Dividend Story Pfizer's payout looks like a safe harbor in a rough market, but the patent clock is ticking and the balance sheet leaves almost no room for error.

  View source ↗
• Newswsj.com·22d ago·Negative

  Pfizer Makes an Unusual Enemy in $2 Billion Fight Over Unwanted Covid-19 Vaccines The drugmaker has targeted air-traffic control fees in a dispute with Poland and Romania.

  View source ↗
• News (Marketaux)finance.yahoo.com·23d ago·Neutral

  How Concerned Should Income Investors Be About Pfizer's Dividend? Pfizer (NYSE: PFE<[+306 characters]

  View source ↗
• News (RSS)fool·23d ago·Neutral

  How Concerned Should Income Investors Be About Pfizer's Dividend? Pfizer has a huge 6% yield and a payout ratio well over 100%, yet the company is still maintaining the dividend.

  View source ↗
• Newsfool.com·23d ago·Negative

  How Concerned Should Income Investors Be About Pfizer's Dividend? Pfizer is one of the world's best-known drug companies, offering a well-above-market dividend yield. The company is facing typical industry headwinds, which make the dividend look risky.

  View source ↗
• Newsproactiveinvestors.com·23d ago·Negative

  Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress across its SkinJect program and a co-development and licensing opportunity with Pfizer, with CEO Raza Bokhari highlighting clinical, partnership and funding developments as the company sharpens its focus on precision oncology and capital-efficient drug development. Bokhari said final SkinJect results published on ClinicalTrials.gov had confirmed the 200-microgram patch a…

  View source ↗
• Newsseekingalpha.com·26d ago·Neutral

  Pfizer: Firing On All Cylinders Pfizer (PFE) remains a strong buy as guidance is reaffirmed and raised, with acquired assets compounding at 18% operationally. PFE's pipeline strength is evident, especially in obesity (berobenatide) and Vyndamax, providing a bridge over the 2028 LOE trough. Valuation is highly attractive: P/E of 9.11, EV/EBITDA of 8.29, and a 6.19% dividend yield, with disciplined capital allocation.

  View source ↗
• News (RSS)yahoo·26d ago·Neutral

  Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks

  View source ↗
• Newszacks.com·27d ago·Neutral

  Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit? PFE's non-COVID growth, oncology pipeline and cost cuts offer a path forward as COVID sales fall and patent losses loom.

  View source ↗
• Newsprnewswire.com·27d ago·Neutral

  Moment Energy Becomes First BESS Provider to Achieve Third-Party Verified non-PFE status, full FEOC Compliance /PRNewswire/ -- Moment Energy today announced rigorous third-party verification of its non-Prohibited Foreign Entity (non-PFE) status and Foreign Entity of

  View source ↗
• News (RSS)fool·27d ago·Positive

  Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior.

  View source ↗
• News (RSS)yahoo·28d ago·Neutral

  Novartis India acquires Pfizer brands for $132m

  View source ↗
• News (RSS)economictimes·28d ago·Neutral

  360 One Group CEO Bhagat buys 1.3 lakh shares of Novartis India for Rs 22 cr Karan Bhagat acquired 1.3 lakh Novartis India shares for nearly Rs 22 crore. His firm Kyrush Investments sold an equal number of shares in the transaction. Novartis India also announced acquiring trademarks from Pfizer for Rs 1,250 crore. Earlier, Novartis AG agreed to sell its stake to a consortium. This deal excluded its innovative medicines business in the country.

  View source ↗
• News (Marketaux)thehindubusinessline.com·28d ago·Positive

  Novartis India Ltd to acquire BP drug trademarks from Pfizer Inc, for ₹1,250 crore Novartis India has inked an agreement to[+204 characters]

  View source ↗
• News247wallst.com·28d ago·Positive

  Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now Pfizer's 5.91% dividend yield anchors the story, and a pipeline finally catching a bid adds meaningful upside. My 24/7 Wall St. price target reflects that.

  View source ↗
• Newsfool.com·28d ago·Neutral

  This Is What I'd Do With Pfizer Stock Right Now Pfizer's stock is down big due to concerns about its future. The company's acquisitions have been paying off and have been boosting its top line.

  View source ↗
• News (RSS)seekingalpha·29d ago·Neutral

  Novartis India inks $132M asset purchase deal with Pfizer for Minipress brands

  View source ↗
• News (RSS)zerohedge·31d ago·Neutral

  …The Amish are the control and keep revealing that there might be a better way. Eliminate the control and you eliminate the embarrassment. This is precisely what both Pfizer and Moderna did after their own tests of the COVID shot: they pushed it on the saline group following first results. In Pennsylvania, opposition arose to this push for industrial inoculation, and understandably so. In the post-COVID era, trust in public health is depleted to near zero. Here is where the current drama picked u…

  View source ↗
• News (RSS)fool·31d ago·Positive

  AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.

  View source ↗
• News247wallst.com·31d ago·Positive

  Pfizer's Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying? Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about keeping that payout alive through what could be the company's toughest stretch in years.

  View source ↗
• Newsfool.com·32d ago·Negative

  3 Things You Need to Know If You Buy Pfizer Stock Today Investors won't start seeing the fruits of Pfizer's current efforts for several more years. A handful of its top-selling drugs will be losing their patent protection in the meantime.

  View source ↗
• Newszacks.com·32d ago·Neutral

  Pfizer (PFE) Up 12.4% Since Last Earnings Report: Can It Continue? Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?

  View source ↗
• Newszacks.com·32d ago·Negative

  Pfizer's Pipeline Strategy Centers on Obesity and Oncology PFE's pipeline is taking center stage as berobenatide and next-generation oncology drugs aim to drive growth from 2028 and beyond.

  View source ↗
• News (RSS)yahoo·34d ago·Neutral

  CFO Turnover at AT&T, Caterpillar, and Pfizer Sparked Rallies. Here’s Why Rivian’s Didn’t.

  View source ↗
• Newszacks.com·35d ago·Positive

  From Padcev to PF-08634404: Pfizer's Oncology Growth Push PFE's oncology growth is led by Padcev, while a broad pipeline and label expansions aim to fuel longer-term gains.

  View source ↗
• News247wallst.com·35d ago·Neutral

  Pfizer and Starbucks: One Turnaround Is Built to Last, and One Isn't Pfizer and Starbucks both raised their outlooks this summer, but a louder recovery and a quieter one are not the same thing, and for investors who need a portfolio to fund actual withdrawals, the difference matters enormously.

  View source ↗
• News (RSS)zerohedge·38d ago·Negative

  …nes FDA Approves 3 New COVID-19 Vaccines Authored by Zachary Stieber via The Epoch Times, The Food and Drug Administration on Aug. 27 approved COVID-19 vaccines from Pfizer, Moderna, and Sanofi. A nurse prepares to give a COVID-19 vaccine to a child in Denver, Colo., on Nov. 3, 2021. (Michael Ciaglo/Getty Images) The new shots from Pfizer and Moderna use the messenger ribonucleic acid (mRNA) platform and target the XFG strain, a subvariant of the JN.1 variant. Regulators also cleared a COVID-19 …

  View source ↗
• News (Marketaux)gurufocus.com·38d ago·Positive

  PFE Looks 5.7% Overvalued on GF Value™ as Dividend Sustainability Shines On August 28, 2026, Pfizer [+293 characters]

  View source ↗
• News (RSS)zerohedge·39d ago·Neutral

  …f so many bubbles simultaneously, it is just a matter of time before the needle comes along and pops them quicker than an athlete collapsing from myocarditis after a Pfizer death jab. The stock market is now more overvalued than it was at the 1929 top and the 2000 dot-com top. Jim Cramer and his fellow boobs and bimbos on CNBC will never warn their non-thinking day trader audience about the imminent collapse of this debt driven bubble. There is a reason Berkshire Hathaway was sitting on $400 bil…

  View source ↗
• Newsglobenewswire.com·39d ago·Neutral

  …rculating variants Shipping will begin immediately to ensure rapid access to this season's vaccine  NEW YORK and MAINZ, GERMANY, August 27, 2026 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies' 2026-2027 COVID-19 vaccine formula targeting the XFG variant (COMIRNATY® XFG; COVID-19 Vaccine, mRNA) for use in adults ages …

  View source ↗
• News (RSS)yahoo·40d ago·Neutral

  Pfizer vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?

  View source ↗
• Newszacks.com·41d ago·Negative

  PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now? PFE and BMY both boast strong oncology portfolios, but Pfizer's valuation and broader diversification make it the more attractive pick now.

  View source ↗
• News (RSS)yahoo·42d ago·Neutral

  Pfizer Stock: Wall Street Sees a Rebound, Here’s Our Price Target

  View source ↗
• News247wallst.com·42d ago·Negative

  Pfizer Stock: Wall Street Sees a Rebound, Here's Our Price Target Our 24/7 Wall St. price target for Pfizer (NYSE:PFE | PFE Price Prediction) points to $32.36 over the next 12 months, implying 15.27% upside from the recent close of $28.07.

  View source ↗
• News (RSS)yahoo·43d ago·Negative

  Pfizer vs. Johnson & Johnson: Which Pharma Giant Is Better Prepared for Its Patent Cliff?

  View source ↗
• News (Marketaux)insidermonkey.com·43d ago·Positive

  Pfizer vs. Johnson & Johnson: Which Pharma Giant Is Better Prepared for Its Patent Cliff? Patent expirations are forcing Pfize[+163 characters]

  View source ↗
• News (RSS)yahoo·43d ago·Negative

  Pfizer vs. Gilead: Which Drugmaker Has the Stronger Growth Story?

  View source ↗
• News (Marketaux)finance.yahoo.com·44d ago·Positive

  Prediction: This Is Where Pfizer Stock Will Be in 2030 Pfizer (NYSE: PFE<[+271 characters]

  View source ↗
• News (RSS)fool·44d ago·Negative

  Prediction: This Is Where Pfizer Stock Will Be in 2030 Pfizer is facing material patent expirations over the next two years, but that will be over by 2030.

  View source ↗
• Newsfool.com·44d ago·Negative

  Prediction: This Is Where Pfizer Stock Will Be in 2030 Pfizer is one of the world's largest and oldest pharmaceutical companies. It faces three notable patent expirations through the end of 2028.

  View source ↗
• PodcastAll In·45d ago·Neutral

  …f this happens. So they can try and everybody will say, okay, and what the Coke CEO will do is redirect all of this capital allocation to outside of America. So will Pfizer, so will I, so will anybody. And then what are you going to do? Take away our passports so you can't travel. So I think it will be a very visible way of just destroying the United States. And you can do that if you want to, but you will see it play out almost instantaneously in the equity markets and in the capital allocation…

  View source ↗
• Newsseekingalpha.com·45d ago·Positive

  …t Investors Will Be Rewarded Pfizer remains significantly undervalued, demonstrating robust profitability and offering an attractive forward dividend yield above 6%. PFE's diversified product roadmap and disciplined capital allocation help offset LOE uncertainties and COVID revenue declines, stabilizing business variability. Oncology pipeline progress, bolstered by the Seagen acquisition, provides credible growth pathways beyond early clinical stages, anchoring the long-term growth optionality.

  View source ↗
• News (RSS)yahoo·46d ago·Negative

  Pfizer Stock Is A Race Between New Drugs And Old Patents

  View source ↗
• News247wallst.com·46d ago·Negative

  Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead Dividend investors have had plenty to cheer in 2026. Pfizer (NYSE:PFE | PFE Price Prediction) is up 19.3% year to date, Chevron (NYSE:CVX) has surged 38.76%, and AbbVie (NYSE:ABBV) has added 19.16%.

  View source ↗
• News247wallst.com·46d ago·Neutral

  Yield Hunters Are Swarming This 6.3%-Dividend Stock—And Big-League Hedge Funds are Quietly Buying the Dip Big-league hedge funds have been taking interest in shares of Pfizer (NYSE:PFE | PFE Price Prediction) of late, with recent 13F filings revealing significant buying activity among the smart money crowd.

  View source ↗
• News247wallst.com·47d ago·Negative

  Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen? Among U.S. large-cap drugmakers, one name has clearly outrun the pack in 2026 so far.

  View source ↗
• 4chan /biz/biz·47d ago·Positive

  MRNA is a reminder to buy some pharma stock bags at big lows from ATH and once in a blue moon it will 100%. Just grab some PFE, NVAX etc and hold it.

  View source ↗
• Newsbenzinga.com·47d ago·Neutral

  Merck Just Raised the Stakes for Pfizer's Cancer Vaccine Ambitions Merck & Company, Inc‘s (NYSE:MRK) latest commitment to personalized cancer vaccines is sending a message that extends well beyond Moderna, Inc. (NASDAQ:MRNA).

  View source ↗